THERAPY DOSSIER · th-ad60ea88c160

Okra pectin, purified on a DEAE cellulose 52 column, compared with crude okra pectin

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 33433910 ↗2020Reported benefit

Okra pectin relieves inflammatory response and protects damaged intestinal barrier in caerulein-induced acute pancreatic model.

MouseChemical/toxinMaleDietary supplementationGiven in advance of induction of pancreatitis

Model: Caerulein-induced acute pancreatitis with associated intestinal barrier damage

Dietary okra pectin reduced serum amylase and lipase, pancreatic oedema, myeloperoxidase activity and pro-inflammatory cytokines while preserving tight junction and antimicrobial peptide expression, with purified pectin outperforming the crude preparation.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…